臭灵丹水提取物的急性毒性及镇痛作用的实验研究

采用上下移动法,醋酸扭体法、热板法、福尔马林致痛试验对臭灵丹水提取物的急性毒性及镇痛作用进行了研究。结果显示：臭灵丹水提取物LD50（腹腔注射）为1．19g／kg;臭灵丹水提取物明显抑制醋酸所致的小鼠扭体数,显著减少福尔马林致痛试验后期小鼠舔足行为;而对热板法所致疼痛无明显作用。表明臭灵丹水提取物具有一定的外周镇痛作用。     

小檗碱的消炎镇痛作用

皮下注射小檗碱明显减少醋酸性小鼠扭体反应次数,半数有效量为3.5mg/kg,仅在皮下注射8mg/kg的大剂量时,对热板法实验表现出镇痛作用。口服60mg/kg 小檗碱明显抑制醋酸提高小鼠腹腔毛细血管通透性;皮下注射20和50mg/kg都显著抑制组胺提高大鼠皮肤毛细血管通透性。给小鼠皮下注射4和8mg/kg小檗碱显著抑制二甲苯引起耳壳肿胀;给大鼠皮下注射20和40mg/kg时显著抑制角叉菜胶引起的足跖肿胀,作用持续7小时以上。小檗碱的消炎镇痛作用随剂量增大而增加。     

苦豆碱对小鼠的急性毒性研究

本文拟探讨苦豆碱对小鼠的急性毒性,并明确其半数致死量(LD_(50))以及毒性靶器官。采用腹腔注射给药方式,给予600.00、480.00、384.00、307.20、245.76 mg/kg的苦豆碱,实验后观察7 d,记录体重变化及自主活动情况,检测苦豆碱对小鼠的急性毒性作用,用加权回归几率法(Bliss)计算LD_(50),并对死亡小鼠进行主要脏器的病理学检查。结果显示,苦豆碱的小鼠LD_(50)为395.62 mg/kg,95%可信限为305.23~535.04 mg/kg,LD_5为143.00 mg/kg,LD95为1094.47 mg/kg。7 d内小鼠体重有增长趋势。病理结果显示,苦豆碱对小鼠的主要毒性靶器官为肝脏。     

两面针提取物(S0)对小鼠镇痛、抗炎和止血作用的研究(英文)

本研究对两面针根的提取物S0进行了镇痛、止血和抗炎药理实验,每种作用选用两种实验方法来评价。镇痛作用采用热板法和扭体法。热板法实验显示,S0在150mg/kg剂量时,小鼠痛阈值明显提高(P<0.01);扭体法实验显示,S0在150mg/kg剂量为时,对冰醋酸致痛的小鼠扭体反应次数减少了70.96%(P<0.01)。抗炎实验采用二甲苯致小鼠耳廓肿胀法及腹腔染料渗出法。二甲苯致炎剂实验表明,S0在150mg/kg剂量时,对二甲苯所致小鼠耳廓肿胀有明显抑制作用,抑制率为63.45%(P<0.01);冰醋酸所致的腹腔毛细血管通透性实验中,S0在150mg/kg和75mg/kg两个剂量组时,对小鼠的抗炎效果分别为52.94%(P<0.01)和52.00%(P<0.01)。止血实验采用毛细玻璃管法和载玻片法。毛细玻璃管实验表明S0在150mg/kg和75mg/kg两个剂量时,凝血时间明显缩短(P<0.01);载玻片实验表明S0在150mg/kg剂量时,凝血时间明显缩短(P<0.01)。总之,两面针中提取物S0对小鼠具有显著的镇痛、止血和抗炎作用。     

两面针提取物(S-O)对小鼠镇痛、抗炎和止血作用的研究

本研究对两面针根的提取物S-O进行了镇痛、止血和抗炎药理实验,每种作用选用两种实验方法来评价。镇痛作用采用热板法和扭体法。热板法实验显示,S-O在150mg/kg剂量时,小鼠痛阈值明显提高（P〈0．01）;扭体法实验显示,S-O在150mg/kg剂量为时,对冰醋酸致痛的小鼠扭体反应次数减少了70．96％（P〈0．01）。抗炎实验采用二甲苯致小鼠耳廓肿胀法及腹腔染料渗出法。二甲苯致炎剂实验表明,S-O在150mg/kg剂量时,对二甲苯所致小鼠耳廓肿胀有明显抑制作用,抑制率为63．45％（P〈0．01）;冰醋酸所致的腹腔毛细血管通透性实验中,S-O在150mg/kg和75mg/kg两个剂量组时,对小鼠的抗炎效果分别为52．94％（P〈0．01）和52．00％（P〈0．01）。止血实验采用毛细玻璃管法和载玻片法。毛细玻璃管实验表明S-O在150mg/kg和75mg/kg两个剂量时,凝血时间明显缩短（P〈0．01）;载玻片实验表明S-O在150mg/kg剂量时,凝血时间明显缩短（P〈0．01）。总之,两面针中提取物S-O对小鼠具有显著的镇痛、止血和抗炎作用。     

番茄叶水提物急性毒性及其对急性炎症的影响

本文观察了番茄叶水提物对小鼠的急性毒性及其对脂多糖诱导急性炎症模型大鼠的影响。采用经典的急性毒性试验方法,观察小鼠口服给予番茄叶水提物的死亡率,按寇氏法计算半数致死量(LD50)。50只SD大鼠随机分为正常组、模型组、阳性药泼尼松5 mg/kg组与番茄叶水提物3.19、1.59 g/kg组,连续给药10 d,每天一次。以腹腔注射脂多糖(LPS)建立急性炎症模型,ELISA法测定血清白细胞介素1(IL-1)、白细胞介素6(IL-6)、肿瘤坏死因子(TNF-α)。结果显示,番茄叶水提物单次灌胃给药的LD50为46.44g/kg,95%可信限为39.52～54.60 g/kg。3.19 g/kg番茄叶水提物可明显降低LPS诱导的急性炎症小鼠血清IL-1、IL-6和TNF-α水平。番茄叶水提物抑制LPS诱导急性炎症的作用机制可能与其降低血清炎症因子水平有关。     

大豆提取物（CKBN）对免疫低下小鼠免疫功能的影响

目的观察大豆提取物（CKBN）对免疫低下小鼠免疫功能的影响。方法腹腔注射环磷酰胺（cyclophosphamide,CTX）建立免疫功能低下小鼠模型,观察1、25、50、100 mg/kg剂量CKBN对免疫低下小鼠免疫功能的影响。结果25 mg/kg组的CKBN可显著增加免疫低下小鼠的脾指数;25、50、100 mg/kg组均能明显抑制环磷酰胺对小鼠外周血白细胞数量的影响,1 mg/kg组可显著提高单核细胞百分率,50 mg/kg组可显著提高中性粒细胞百分率;100 mg/kg组的IgG2a水平高于环磷酰胺组;1、25、50 mg/kg可显著提高腹腔巨噬细胞的吞噬功能;25 mg/kg组可显著提高NK细胞杀伤活性。结论CKBN能显著增强CTX造成的免疫低下小鼠的免疫功能。     

荣骨定痛膏的镇痛抗炎作用及其机制

目的:研究荣骨定痛膏镇痛、抗炎作用及其机制。方法:采用热板法、醋酸扭体法来观测荣骨定痛膏的镇痛作用,采用耳廓肿胀法、足肿胀法来考察荣骨定痛膏的抗炎作用,测定渗出液中总蛋白与白三烯B4(LTB4)来研究荣骨定痛膏的抗炎机制。在给药的基础上观测痛阈值、肿胀度等指标;复制气囊滑膜炎,取小鼠66只,随机分为正常对照组、模型对照组、阳性对照组(扶他林0.8 mg/d)、荣骨定痛膏低、中、高剂量组(荣骨定痛膏30 mg/d、60 mg/d、120 mg/d)进行实验。结果:30 mg/d、60 mg/d、120 mg/d的荣骨定痛膏可明显提高小鼠热板痛阈延长百分率、延长扭体潜伏期并减少15 min内的扭体次数,缓解小鼠耳廓肿胀度与足肿胀度(P0.05,P0.01),显示出一定的抗炎、镇痛作用。对气囊滑膜炎模型动物,30 mg/d、60 mg/d、120 mg/d荣骨定痛膏可降低渗出物中总蛋白及LTB4的含量(P0.05,P0.01)。结论:荣骨定痛膏具有一定的镇痛抗炎作用,抑制LTB4的合成是其抗炎机制之一。     

乌金草挥发油镇痛作用的研究

采用热板法和醋酸扭体法两种经典的镇痛模型对乌金草挥发油进行了初步的镇痛作用研究。结果表明,乌金草挥发性成分具有显著的镇痛作用,能明显延长小鼠热板痛阈值,有效降低小鼠因醋酸所致扭体反应次数。在给药1mL/kg剂量和2mL/kg剂量时,该挥发油均具有明显的镇痛效果,且有一定的量效关系。     

溴隐亭和巴氯芬对吗啡诱导成瘾后戒断症状的协同抑制作用

皮下递增注射吗啡(25、50、75、100、125、150mg/kg)建立小鼠身体依赖动物模型,把6mg/kg纳络酮作用下的小鼠跳跃症状作为成瘾后戒断的行为学观测指标,检测DA受体激动剂溴隐亭和GABAB受体激动剂巴氯芬对戒断行为的影响;同时进一步研究激动二受体在戒断过程中的作用。结果表明:溴隐亭低剂量(10mg/kg)无抑制戒断症状的作用,中、高剂量(20、30mg/kg)能够明显抑制戒断症状;巴氯芬低、中剂量(0.5、1.0mg/kg)无抑制戒断症状的作用,高剂量(1.5mg/kg)则可以抑制戒断症状的作用。当无抑制作用剂量的溴隐亭(10mg/kg)和巴氯芬(1.0mg/kg)联合应用时能够明显抑制小鼠的戒断症状,说明此二受体在吗啡成瘾后戒断期间功能上具有协同作用,能够很好地抑制纳络酮诱导的成瘾小鼠跳跃症状。     

Opioid activity of C8813, a novel and potent opioid analgesic

Compound trans-4-(p-bromophenyl)-4-(dimethylamino)-1-(2-thiophen-2-yl-ethyl)-cyclohexanol (C8813), structurally unrelated to morphine, is a novel analgesic. The present study examined the antinociception, opioid receptor selectivity and in vitro activity of C8813. The antinociceptive activity was evaluated using mouse hot plate and acetic acid writhing tests. In mouse hot plate test, the antinociceptive ED(50) of C8813 was 11.5 microg/kg, being 591 times and 3.4 times more potent than morphine and fentanyl respectively. In mouse writhing test, the antinociceptive ED(50) of C8813 was 16.9 microg/kg, being 55 times and 2.3 times more active than morphine and fentanyl respectively. In the opioid receptor binding assay, C8813 showed high affinity for mu-opioid receptor (K(i) = 1.37 nM) and delta-opioid receptor (K(i) = 3.24 nM) but almost no affinity for kappa-opioid receptor (at 1 microM). In the bioassay, the inhibitory effect of C8813 in the guinea-pig ileum (GPI) was 16.5 times more potent than in the mouse vas deferens (MVD). The inhibitory effects of C8813 in the GPI and MVD could be antagonized by mu-opioid receptor antagonist naloxone and delta-opioid receptor antagonist ICI174,864 respectively. However, the inhibitory effect of C8813 in the rabbit vas deferens was very weak. These results indicated that C8813 was a potent analgesic and a high affinity agonist for the mu- and delta-opioid receptors.     

Thiorphan potentiation of stress-induced analgesia in the mouse

Experiments were done to examine the analgesic effect of thiorphan alone or in combination with stress in mice. Analgesia was assessed by measuring jump latencies from a 55 degrees C hot plate. Thiorphan exhibited weak analgesic properties evidenced by significant increases in jump latencies only after 300 mg/kg i.p. Additional experiments were done to see the effect of i.c.v. administration of thiorphan in the mouse hot plate test. Control experiments revealed that either i.c.v. saline or sham caused naloxone reversible analgesia which was potentiated by thiorphan (100 mg/kg i.p.). Immobilization stress-induced analgesia was also potentiated by thiorphan (100 mg/kg i.p.) and antagonized by naloxone (10 mg/kg i.p.). The results suggest that stress-induced analgesia in the mouse is associated with an endogenous opioid mechanism which is potentiated when enkephalin degradation is inhibited by thiorphan.     

On the role of the 200-kDa neurofilament protein at the developing neuromuscular junction

To examine whether the 200-kDa neurofilament protein (200K NFP) is involved in mechanically stabilizing axons, we studied the developmental appearance of immunoreactivity to nonphosphorylated and phosphorylated 200K NFP at the neuromuscular junction. Polyinnervated rat muscle fibers become singly innervated during the first 3 weeks of postnatal life through the process of synapse elimination. If production or post-translational modification of the 200K NFP is actively involved in imparting mechanical stability on neuromuscular synapses, then the selective presence of this protein in only one of several axons at each developing end plate region might make that one axon selectively resistant to elimination. The remaining axons would then be eliminated. Immunoreactivity to the 200K NFP is present on Gestational Day 14 and can be seen in more than one preterminal axon in the end plate region of a muscle fiber during the period of synapse elimination. These results suggest that the 200K NFP is present and phosphorylated early in development and, although the 200K NFP may increase the mechanical stability of axons, this increased stability does not determine the final outcome of synapse elimination.     

Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum Accumulation

Oxaliplatin is a platinum-based anticancer drug used to treat metastatic colorectal, breast, and lung cancers. While oxaliplatin kills cancer cells effectively, it exhibits several side effects of varying severity. Neuropathic pain is commonly experienced during treatment with oxaliplatin. Patients describe symptoms of paresthesias or dysesthesias that are triggered by cold (acute neuropathy), or as abnormal sensory or motor function (chronic neuropathy). In particular, we found that aluminum levels were relatively high in some cancer patients suffering from neuropathic pain based on clinical observations. Based on these findings, we hypothesized that aluminum accumulation in the dorsal root ganglion (DRG) in the course of oxaliplatin treatment exacerbates neuropathic pain. In mice injected with oxaliplatin (three cycles of 3 mg/kg i.p. daily for 5 days, followed by 5 days of rest), we detected cold allodynia using the acetone test, but not heat hyperalgesia using a hot plate. However, co-treatment with aluminum chloride (AlCl_3∙6H₂O; 7 mg/kg i.p. for 14 days: equivalent 0.78 mg/kg of elemental Al) and oxaliplatin (1 cycle of 3 mg/kg i.p. daily for 5 days, followed by 5 days of rest) synergistically induced cold allodynia as well as increased TRPAl mRNA and protein expression. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) analysis showed a significant increase in aluminum concentrations in the DRG of mice treated with aluminum chloride and oxaliplatin compared to aluminum chloride alone. Similarly, in a mouse induced-tumor model, aluminum concentrations were increased in DRG tissue and tumor cells after oxaliplatin treatment. Taken together, these findings suggest that aluminum accumulation in the DRG may exacerbate neuropathic pain in oxaliplatin-treated mice.     

克班宁的镇痛作用部位及作用机制探讨

以探究克班宁的镇痛作用部位并初步明确其镇痛机制为目的。采用小鼠足趾注射甲醛法、热板法及腹腔注射醋酸(扭体法)所致疼痛模型,探讨克班宁的镇痛作用;以小鼠输精管经壁电刺激法,了解克班宁对吗啡受体的影响。结果发现克班宁在3.2 mg/kg时对三种疼痛模型均显示明显的抑制作用,并能明显抑制小鼠输精管经壁电刺激所引起的收缩,且该收缩不能被纳络酮所拮抗。因此,克班宁可能具有中枢样镇痛作用,但作用机制与吗啡受体无关。     

Glucagon is an antagonist of morphine bradycardia and antinociception

Glucagon and its receptors have been identified within the mammalian brain, and their anatomical distribution correlates well with the distribution of opioid peptides and their receptors. To evaluate possible physiological interactions between these two peptidergic systems, we examined the effects of glucagon on two opioid responses - bradycardia and antinociception. Glucagon administered either intravenously (iv) (100-1000 micrograms/kg) or intracerebroventricularly (icv) (5 micrograms) significantly attenuated morphine-induced (200 micrograms/kg, iv) bradycardia without producing any alterations in cardiovascular parameters when given alone. Furthermore, glucagon did not antagonize the bradycardia produced by phenyldiguanide (10 micrograms/kg, iv), a non-opioid substance. Peripheral (1 mg/kg, iv) and central (5 micrograms, icv) glucagon pretreatment antagonized morphine-induced (7.5 mg/kg, intraperitoneal) antinociception by 67% and 86%, respectively, at 30 minutes (as determined by the hot plate test). Glucagon treatment alone at these doses did not alter baseline response latencies. In both cases, central injections of glucagon were more effective than iv injections in antagonizing morphine's effects. These findings demonstrate a central action for glucagon and provide the first evidence that this neuropeptide may function as an endogenous antagonist of opioid actions.     

Antinociceptive activity of metapramine in mice. Relationship with its pharmacokinetic properties.

The antinociceptive effect of acutely and chronically (every brain elimination half-life time) administered metapramine, a tricyclic antidepressant without anticholinergic or cardiotoxic effects, was studied in three different pain tests. In the hot plate test, its action was more potent when jumping was used as a pain parameter (acute ED50 = 19 +/- 3 mg/kg, i.p.) than when pain was assessed by licking of forepaws (only 20 mg/kg, i.p. was weakly active). Five chronic doses of 15 mg/kg were as active in the tail-flick test as an acute dose of 20 mg/kg (only active dose). Metapramine was more effective in the PBQ-induced writhing test after acute (ED50 = 9.9 +/- 0.1 mg/kg, i.p.) and chronic administration. A significant linear correlation was found between the effect in this test and plasma and overall brain levels of metapramine. No correlation was observed with levels of its three desmethylated metabolites. The usefullness of using a well-defined pattern of administration based on pharmacokinetic parameters and the involvement of monoaminergic mechanisms and of some metabolites of metapramine are discussed.     

Cannabinoids and pain responses: a possible role for prostaglandins

The principal metabolite of delta 1-THC, delta 1-THC-7-oic acid exhibits significant analgesic action in the mouse hot plate test. The parent delta 1-THC has a similar effect when measured at later time points; however, 10 min after drug administration, a pronounced hyperalgesia is seen. This hyperalgesia can be inhibited by prior administration of either indomethacin or delta 1-THC-7-oic acid, presumably because of their ability to inhibit eicosanoid synthesis. Administration of prostaglandin E2 (PGE2), at doses that were a small fraction of the delta 1-THC given, resulted in a strong hyperalgesic response. Unlike delta 1-THC, the metabolite does not produce a cataleptic state in the mouse, which eliminates this as a basis for the hot plate response. The evidence presented is consistent with a mechanism in which the metabolite inhibits eicosanoid synthesis whereas the parent drug elevates tissue levels of prostaglandins.